company background image
MRNS logo

Marinus Pharmaceuticals NasdaqGM:MRNS 株式レポート

最終価格

US$0.33

時価総額

US$18.1m

7D

-12.2%

1Y

-95.0%

更新

04 Nov, 2024

データ

会社財務 +

Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS 株式レポート

時価総額:US$18.1m

MRNS 株式概要

マリナス・ファーマシューティカルズ社は、希少な遺伝性てんかんやその他の発作性疾患を患う患者のための治療薬の開発と商業化に注力している製薬会社である。

MRNS ファンダメンタル分析
スノーフレーク・スコア
評価5/6
将来の成長2/6
過去の実績0/6
財務の健全性0/6
配当金0/6

Marinus Pharmaceuticals, Inc. 競合他社

価格と性能

の歴代最高値、変動、値下がりまとめMarinus Pharmaceuticals
過去の株価
現在の株価US$0.33
52週高値US$11.26
52週安値US$0.26
ベータ1.13
11ヶ月の変化-81.58%
3ヶ月変化-71.49%
1年変化-95.03%
33年間の変化-97.44%
5年間の変化-92.87%
IPOからの変化-98.98%

最新ニュース

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Sep 20
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Sep 20
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Apr 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 08
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Dec 22
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Sep 22
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Jun 12
Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

May 16
Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Oct 12
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Marinus Pharmaceuticals: Positive News Flow Of Note

Sep 22

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Aug 29

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Jul 28

Revisiting Marinus Pharmaceuticals

May 05

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27
Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption

Feb 28

株主還元

MRNSUS PharmaceuticalsUS 市場
7D-12.2%-3.7%-1.6%
1Y-95.0%17.2%30.8%

業界別リターン: MRNS underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.

リターン対市場: MRNS underperformed the US Market which returned 30.8% over the past year.

価格変動

Is MRNS's price volatile compared to industry and market?
MRNS volatility
MRNS Average Weekly Movement28.8%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

安定した株価: MRNS's share price has been volatile over the past 3 months compared to the US market.

時間の経過による変動: MRNS's weekly volatility has increased from 20% to 29% over the past year.

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
2003166Scott Braunsteinmarinuspharma.com

マリナス・ファーマシューティカルズ・インクは、希少な遺伝性てんかんやその他の発作性疾患を患う患者を対象とした治療薬の開発と商業化に注力している製薬企業である。ZTALMY(ガナキソロン)は、サイクリン依存性キナーゼ様5欠乏症に伴うてんかん発作の治療薬として、成人および小児患者を対象に、急性期および慢性期、入院および自己投与の環境において経口懸濁液を提供している。同社のZTALMY製品候補は、シナプスおよびシナプス外GABAA受容体に作用し、抗けいれん、抗うつ、抗不安のターゲットとなる。ガナキソロンは、PCDH19関連てんかんや結節性硬化症などの遺伝性てんかんの治療薬として開発中である。Marinus Pharmaceuticals, Inc.は、Purdue Neuroscience CompanyおよびCyDex Pharmaceuticals, Inc.とライセンス契約を締結しており、Orion CorporationおよびTenacia Biotechnology (Shanghai) Co., Ltd.と共同研究契約を締結している。マリナス・ファーマシューティカルズ・インクは2003年に設立され、ペンシルバニア州ラドナーに本社を置いています。

Marinus Pharmaceuticals, Inc. 基礎のまとめ

Marinus Pharmaceuticals の収益と売上を時価総額と比較するとどうか。
MRNS 基礎統計学
時価総額US$18.06m
収益(TTM)-US$149.24m
売上高(TTM)US$30.26m

0.6x

P/Sレシオ

-0.1x

PER(株価収益率

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
MRNS 損益計算書(TTM)
収益US$30.26m
売上原価US$97.43m
売上総利益-US$67.16m
その他の費用US$82.08m
収益-US$149.24m

直近の収益報告

Jun 30, 2024

次回決算日

該当なし

一株当たり利益(EPS)-2.71
グロス・マージン-221.93%
純利益率-493.14%
有利子負債/自己資本比率-200.5%

MRNS の長期的なパフォーマンスは?

過去の実績と比較を見る